Skip to main content

Jasmine Zain MD

Jasmine Zain MD, is an associate clinical professor in the Department of Hematology & Hematopoietic Cell Transplantation. Additionally, she is the Tim Nesvig Lymphoma Research Fellow, as well as director of the T cell Lymphoma Program at the Toni Stephenson Lymphoma Center at City of Hope.

Dr Zain obtained her medical degree from Fatima Jinnah Medical College for Women in Lahore Pakistan. She went on to complete an internship and residency at North Shore Hospital of Forest Hills in Forest Hills, NY, followed by a hematology/oncology fellowship at New York University Medical Center. She then took a position at The Brooklyn Hospital as an attending physician, followed by an appointment as assistant professor in the Department of Medicine at the University of Connecticut.

Dr Zain first joined City of Hope where she specialized in the treatment of patients with cutaneous T-cell lymphoma, allogeneic stem cell transplantation, and early phase clinical trials in hematologic malignancies. She left City of Hope to assume a leadership position as director of the bone marrow transplant program at New York University Langone Medical Center, before joining the faculty at Columbia University in 2012.

Triple-board certified in hematology, oncology and internal medicine, Dr Zain is an active member of several professional associations, and has published more than 78 peer-reviewed publications, abstracts, and book chapters. She served as an Associate Editor for two journals in her field – Clinical Lymphoma and Myeloma, and Clinical Cancer Research – and has been invited to speak both nationally and internationally.

Dr Zain is a superb clinician, a productive and creative clinical researcher, and an outstanding and experienced teacher.

print
PRINT

Latest contributions from Jasmine Zain

New Content Item

26-01-2017 | Hematologic cancers | Editorial | Article

Immunotherapy comes of age in blood cancers

Advisory Board member Jasmine Zain discusses the development of various immunotherapy approaches and their potential clinical benefits for patients with blood cancers.